Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 2/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378331 | 1.00 | ENPP3 (0.36) | ENPP3ENPP1AXLPRKCICDC7 | |
| SCHEMBL15280118 | 0.81 | CCR1 (0.38) | — | |
| SCHEMBL29660466 | 0.80 | MGAM (0.34) | PRKCI | |
| SCHEMBL1002153 | 0.80 | — | — | |
| SCHEMBL2794776 | 0.80 | — | — | |
| SCHEMBL794853 | 0.80 | MGAM (0.34) | PRKCI | |
| SCHEMBL29660486 | 0.80 | — | — | |
| SCHEMBL12594299 | 0.79 | — | — | |
| SCHEMBL15155025 | 0.79 | MGAM (0.34) | PRKCI | |
| SCHEMBL4285909 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867716-A | Solid forms of FGFR inhibitors and methods for their preparation | 因赛特公司 | 2021-05-28 | — | — | CN | claimed |
| EP-3788047-A2 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | Incyte Corporation (US) | 2021-03-10 | — | — | EP | claimed |
| US-20190337948-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | WILMINGTON PHARMATECH | 2019-11-07 | — | — | US | claimed |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12552792-B2 | Solid forms of an FGFR inhibitor and processes for preparing the same | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250276970-A1 | DERIVATIVES OF AN FGFR INHIBITOR | INCYTE CORPORATION | 2025-09-04 | — | — | US | disclosed |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250042895-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-02-06 | — | — | US | disclosed |
| US-20240425506-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | INCYTE CORPORATION | 2024-12-26 | — | — | US | disclosed |
| US-12168660-B2 | Derivatives of an FGFR inhibitor | INCYTE CORPORATION (US) | 2024-12-17 | — | — | US | disclosed |
| EP-3788047-B1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | INCYTE CORP (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2007007919-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006124731-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1539763-A1 | AZAINDOLE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004009601-A1 | AZAINDOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337948-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | FGFR1, FGFR2, FGFR3 | ENPP3 3507/4885ENPP1 3026/4885AXL 15/4885 |
| US-12168660-B2 | Derivatives of an FGFR inhibitor | FGFR1, FGFR2, FGFR4 | ENPP3 4471/4885ENPP1 4451/4885AXL 77/4885 |
| US-20240425506-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | FGFR1, FGFR2, FGFR3 | ENPP3 3507/4885ENPP1 3026/4885AXL 15/4885 |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | ENPP3 229/4885ENPP1 494/4885AXL 1363/4885 |
| US-20250276970-A1 | DERIVATIVES OF AN FGFR INHIBITOR | FGFR1, FGFR2, FGFR4 | ENPP3 4471/4885ENPP1 4451/4885AXL 77/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | ENPP3 2749/4885ENPP1 2117/4885AXL 388/4885 |
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | ENPP3 1094/4885ENPP1 1152/4885AXL 812/4885 |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | ENPP3 1296/4885ENPP1 1875/4885AXL 1887/4885 |
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | ENPP3 2945/4885ENPP1 2354/4885AXL 103/4885 |
| US-12552792-B2 | Solid forms of an FGFR inhibitor and processes for preparing the same | FGFR2, FGFR1, FGF2 | ENPP3 4592/4885ENPP1 4117/4885AXL 101/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | ENPP3 2859/4885ENPP1 2319/4885AXL 82/4885 |
| US-20250042895-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | ULK1, ULK2, ULK3 | ENPP3 1425/4885ENPP1 1337/4885AXL 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.